Results 121 to 130 of about 32,649 (166)

Characterization of Self-Assembled Monolayers of Peptide Mimotopes of CD20 Antigen and Their Binding with Rituximab

Langmuir, 2015
CD20, expressed in greater than 90% of B-lymphocytic lymphomas, is a target for antibody therapy. Rituximab is a chimeric therapeutic monoclonal antibody (mAb) against the protein CD20, allowing it to destroy B cells and to treat lymphoma, leukemia, transplant rejection, and autoimmune disorder.
Norman, Leo, Yuqin, Shang, Jing-jiang, Yu, Xiangqun, Zeng   +3 more
openaire   +2 more sources

The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Expert Opinion on Biological Therapy, 2011
Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic
Musto P, D'Auria F
openaire   +2 more sources

In Silico Analysis for Determination and Validation of Human CD20 Antigen 3D Structure

International Journal of Peptide Research and Therapeutics, 2017
CD20 has been known as an attractive therapeutic target for refractory diseases such as B-cell chronic lymphocytic leukemia, rheumatoid arthritis and multiple sclerosis. Determining the 3D structure of the CD20 antigen could help to achieve a better deduction of its functions and its interactions with ligands.
Zahra Payandeh, Masoumeh Rajabibazl, Yousef Mortazavi, Azam Rahimpour   +3 more
openaire   +1 more source

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
Rituximab is a chimeric antibody with human gamma-1 and kappa constant regions and murine variable regions. It recognizes the CD20 antigen, a pan B-cell marker. Therapeutic trials in patients with B-cell non-Hodgkin's lymphoma (NHL) have shown significant efficacy with a primary response rate of 50%, and a secondary response rate of 44% after repeat ...
T A, Davis, D K, Czerwinski, R, Levy
openaire   +1 more source

Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia

Cytokines, Cellular & Molecular Therapy, 2000
Chimeric CD20 monoclonal antibody as alternative therapy in relapsed low-grade non-Hodgkin's lymphoma (NHL) has produced responses in nearly 50% of patients. Augmenting CD20 expression on tumor cells and/or inducing its expression may increase the cell kill and effectiveness of antibody therapy. Peripheral blood lymphocytes from 19 patients with B-cell
S, Sivaraman, P, Venugopal, R, Ranganathan, C G, Deshpande, X, Huang, A, Jajeh, S A, Gregory, T, O'Brien, H D, Preisler   +8 more
openaire   +2 more sources

GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes

Leukemia Research, 2005
CD20 antigen expression in B-chronic lymphocytic leukemia (B-CLL) is at significantly lower levels than in non-Hodgkins lymphoma, which may affect the degree of anti-CD20 antibody binding. Low density of CD20 expression on malignant cells may explain the lower response rates to anti-CD20 monoclonal antibody, observed in B-CLL.
Yagci, M, Akar, I, Sucak, GT, Haznedar, R   +3 more
openaire   +3 more sources

Generation and functional comparison of anti-CD20 chimeric antigen receptors

2019
Chimeric antigen receptor (CAR) T-cell therapy has proven effective, particularly in targeting relapsed, refractory haematological malignancies. However, optimal CAR design is not fully understood. It is known that the antigen epitope position, affinity of interaction and the length of the CAR construct can all impact function, but these factors often ...
openaire   +2 more sources

CD20 Surface Antigen

2013
Christin A. Knowlton, Michelle Kolton Mackay, Tod W. Speer, Robyn B. Vera, Douglas W. Arthur, David E. Wazer, Rachelle Lanciano, James H. Brashears, Christin A. Knowlton, Michelle Kolton Mackay, Filip T. Troicki, Jaganmohan Poli, Theodore E. Yaeger, Theodore E. Yaeger, Stephan Mose, Filip T. Troicki, Jaganmohan Poli, Anthony E. Dragun, Ramesh Rengan, Charles R. Thomas, Bernadine R. Donahue, Jay S. Cooper, Tod W. Speer, Filip T. Troicki, Jaganmohan Poli, Tod W. Speer, Patrizia Guerrieri, Paolo Montemaggi, Carsten Nieder, Tod W. Speer, John P. Christodouleas, Caspian Oliai, Theodore E. Yaeger, Curt Heese, Carlos A. Perez, Wade L. Thorstad, Darek Michalski, M. Saiful Huq, Christin A. Knowlton, Michelle Kolton Mackay, Brandon J. Fisher, Erik Limbergen, Bok Ai Choo, Jiade J. Lu, Luther W. Brady, Brandon J. Fisher, Larry C. Daugherty, Claudia Rübe, Daniel Yeung, Jatinder Palta, Bradley J. Huth, Anthony E. Dragun, Bradley J. Huth, Bradley J. Huth, Claudia E. Rübe, Jay E. Reiff, Theodore E. Yaeger, Theodore E. Yaeger, Tod W. Speer, Anthony E. Dragun, Carsten Nieder, Filip T. Troicki, Jaganmohan Poli, Volker Budach, Edward J. Gracely, Timothy Holmes, Daniel J. Scanderbeg, John P. Christodouleas, Timothy Holmes, Brandon J. Fisher, Larry C. Daugherty, Tod W. Speer, Johannes Classen, Stephan Mose, Curt Heese, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Claudia Rübe   +78 more
openaire   +1 more source

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

Proceedings of the National Academy of Sciences of the United States of America, 2023
Fredrik Piehl, Martin Weber, Tjalf Ziemssen   +2 more
exaly  

Development of an SPR-based binding assay for characterization of anti-CD20 antibodies to CD20 expressed on extracellular vesicles

Analytical Biochemistry, 2022
Yonglian Sun, James Koerber, Yongmei Chen   +2 more
exaly